Department Of Zoology

Permanent URI for this communityhttps://kr.cup.edu.in/handle/32116/62

Browse

Subject: search.filters.subject.mouse

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    The creation of selenium nanoparticles decorated with troxerutin and their ability to adapt to the tumour microenvironment have therapeutic implications for triple-negative breast cancer
    (Royal Society of Chemistry, 2023-02-09T00:00:00) Saranya, Thiruvenkataswamy; Kavithaa, Krishnamoorthy; Paulpandi, Manickam; Ramya, Sennimalai; Winster, Sureshbabu Harysh; Mani, Geetha; Dhayalan, Sangeetha; Balachandar, Vellingiri; Narayanasamy, Arul
    Despite advancements in treatment, managing aggressive types of breast cancer, particularly Triple Negative Breast Cancer (TNBC), remains a daunting task. Newer chemotherapeutics enhance the multidrug resistance in cancer cells, making them untreatable. The current research work was framed to develop a novel therapeutic target by utilizing the flavanol, troxerutin (TXN) as a drug of interest to target TNBC. And also, to increase the efficiency of the drug at the target site, a nanocarrier called selenium nanoparticles (SeNPs) has been exploited. Thus, the anticancer efficacy of TXN and Se-TXN against TNBC (in vitro and in vivo) has been compared and analysed in the present study. Se-TXN was synthesized by a precipitation approach and characterized by diverse analytical techniques, which confirmed the successful loading of TXN on the SeNPs. The inhibitory concentration (IC50) of Se-TXN was determined to be 6.5 � 0.5 ?g mL?1 according to the in vitro data. Even at lower concentrations, the existence of apoptotic bodies shows that Se-TXN is effective against TNBC. Additionally, the Se-TXN expression study shows that the activation of the caspase cascade pathway, which results in apoptosis, occurs from the downregulation of anti-apoptotic proteins and genes and the upregulation of pro-apoptotic proteins and genes. And the in vivo investigations like histopathology, hematology and biochemical parameters revealed that the Se-TXN had significantly lowered the tumour volume of treated Balb/C mice without having any significant systemic toxicity when compared to other treatment groups. Altogether, our data suggests the efficacy of Se-TXN nanoconjugates as an effective management therapy for treating TNBC. � 2023 The Royal Society of Chemistry.
  • No Thumbnail Available
    Item
    Ontogeny of TR?1 expression in the mouse testis and epididymis during postnatal development
    (John Wiley and Sons Inc, 2022-06-27T00:00:00) Sarkar, Debarshi; Jaiswal, Asmita; Singh, Shio Kumar
    Thyroid hormone (T3) acts on the testis via thyroid hormone receptor alpha 1 (TR?1), though the cellular localization of TR?1 in testis remains controversial. Studies on the presence of TR?1 in the epididymis are also lacking. The present study, therefore, examined the cellular localization and expression pattern of TR?1 in testis and epididymis of Parkes mice during postnatal development. Immunohistochemical results showed localization of TR?1 in interstitial and tubular compartments of the testis all through the development. On postnatal day (PND) 14, only leptotene spermatocytes showed TR?1-immunoreactivity in the testis, while at PND 28, 42, and 90, a diverse staining pattern for TR?1 was seen in almost all the seminiferous tubules mainly in leptotene spermatocytes, round and elongating spermatids, and in Leydig cells. Further, qRT-PCR and immunoblot analyses showed that TR?1 was expressed in the testis at the transcript as well as protein level throughout the postnatal development. TR?1 was also seen in principal cells of the epididymis, with maximal expression at PND 90. TR?1 was also present in cauda epididymidal spermatozoa of adult mice at PND 90. The results suggest that TR?1 is expressed in the testis and epididymis and that it may help to regulate the spermatogenic process and male fertility. � 2022 Wiley-VCH GmbH.